No Data
No Data
No Data
No Data
No Data
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution
MT NewswiresMar 28 05:30
Merrimack Receives $225M Milestone Payment From Ipsen
Seeking AlphaMar 28 04:36
Merrimack Secures $225M Milestone Payment From Ipsen; Says It Is Unlikely That Any Additional Milestone Payments Will Become Payable
The company has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-l
BenzingaMar 28 04:34
Merrimack Receives $225 Million Milestone Payment From Ipsen
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
BusinesswireMar 28 04:30
Merrimack Pharmaceuticals Proposes Liquidation Plan
TipRanksMar 8 05:52
Merrimack FY23 EPS $(0.08) Per Basic Share
Merrimack FY23 EPS $(0.08) Per Basic Share
BenzingaMar 8 05:34
No Data
No Data